

# William A Robinson

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8079363/publications.pdf>

Version: 2024-02-01

199  
papers

9,082  
citations

36303

51  
h-index

46799

89  
g-index

201  
all docs

201  
docs citations

201  
times ranked

10881  
citing authors

#	ARTICLE	IF	CITATIONS
1	Adjuvant Therapy for Stage III Melanoma Without Immediate Completion Lymph Node Dissection. <i>Annals of Surgical Oncology</i> , 2022, 29, 806-815.	1.5	7
2	Expression Differences in BCL2 Family Members between Uveal and Cutaneous Melanomas Account for Varying Sensitivity to BH3 Mimetics. <i>Journal of Investigative Dermatology</i> , 2022, 142, 1912-1922.e7.	0.7	3
3	BRAF Modulates Lipid Use and Accumulation. <i>Cancers</i> , 2022, 14, 2110.	3.7	3
4	Variant Calling in Next Generation Sequencing Data. , 2021, , 129-140.		0
5	Melanocyte Precursors in the Hair Follicle Bulge of Repigmented Vitiligo Skin Are Controlled by RHO-GTPase, KCTD10, and CTNNB1 Signaling. <i>Journal of Investigative Dermatology</i> , 2021, 141, 638-647.e13.	0.7	7
6	Studying Immunotherapy Resistance in a Melanoma Autologous Humanized Mouse Xenograft. <i>Molecular Cancer Research</i> , 2021, 19, 346-357.	3.4	6
7	Abstract PO048: Loss of intra-tumoral RIG-I immune signaling is a potential microbiome-mediated mechanism underlying poor anti-tumor immunity and immunotherapy resistance in mucosal melanoma. , 2021, , .		1
8	Targeting the RIG-I-like receptor signaling pathway to improve the efficacy of immunotherapy in mucosal and uveal melanoma.. <i>Journal of Clinical Oncology</i> , 2021, 39, e21593-e21593.	1.6	1
9	Pembrolizumab and all-trans retinoic acid combination treatment of advanced melanoma.. <i>Journal of Clinical Oncology</i> , 2021, 39, 9536-9536.	1.6	4
10	A Novel Regimen for Treating Melanoma: MCL1 Inhibitors and Azacitidine. <i>Pharmaceuticals</i> , 2021, 14, 749.	3.8	2
11	Targeting CDK4/6 Represents a Therapeutic Vulnerability in Acquired BRAF/MEK Inhibitor-Resistant Melanoma. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 2049-2060.	4.1	16
12	ASO Visual Abstract: Adjuvant Therapy for Stage III Melanoma without Immediate Completion Lymph Node Dissection. <i>Annals of Surgical Oncology</i> , 2021, 28, 738-739.	1.5	1
13	Diagnosis of mast cell activation syndrome: a global consensus-2. <i>Diagnosis</i> , 2021, 8, 137-152.	1.9	59
14	Safety and efficacy of avapritinib in advanced systemic mastocytosis: the phase 1 EXPLORER trial. <i>Nature Medicine</i> , 2021, 27, 2183-2191.	30.7	78
15	Whole-genome sequencing of acral melanoma reveals genomic complexity and diversity. <i>Nature Communications</i> , 2020, 11, 5259.	12.8	102
16	Simultaneously Inhibiting BCL2 and MCL1 Is a Therapeutic Option for Patients with Advanced Melanoma. <i>Cancers</i> , 2020, 12, 2182.	3.7	21
17	Pre-Treatment Mutational and Transcriptomic Landscape of Responding Metastatic Melanoma Patients to Anti-PD1 Immunotherapy. <i>Cancers</i> , 2020, 12, 1943.	3.7	18
18	MCL1 inhibitors S63845/MIK665 plus Navitoclax synergistically kill difficult-to-treat melanoma cells. <i>Cell Death and Disease</i> , 2020, 11, 443.	6.3	45

#	ARTICLE	IF	CITATIONS
19	Clinical and molecular features of subungual melanomas are site-specific and distinct from acral melanomas. <i>Melanoma Research</i> , 2020, 30, 562-573.	1.2	18
20	A nomogram to predict node positivity in patients with thin melanomas helps inform shared patient decision making. <i>Journal of Surgical Oncology</i> , 2019, 120, 1276-1283.	1.7	14
21	Targeted Genomic Profiling of Acral Melanoma. <i>Journal of the National Cancer Institute</i> , 2019, 111, 1068-1077.	6.3	118
22	Interleukin-37 is highly expressed in regulatory T cells of melanoma patients and enhanced by melanoma cell secretome. <i>Molecular Carcinogenesis</i> , 2019, 58, 1670-1679.	2.7	19
23	A familial germline mutation in KIT associated with achalasia, mastocytosis and gastrointestinal stromal tumors shows response to kinase inhibitors. <i>Cancer Genetics</i> , 2019, 233-234, 1-6.	0.4	11
24	IL-6 and IL-8 Are Linked With Myeloid-Derived Suppressor Cell Accumulation and Correlate With Poor Clinical Outcomes in Melanoma Patients. <i>Frontiers in Oncology</i> , 2019, 9, 1223.	2.8	88
25	Inflammatory side effects of BRAF and MEK inhibitors. <i>Melanoma Research</i> , 2019, 29, 522-526.	1.2	12
26	Inhibition of MERTK Promotes Suppression of Tumor Growth in BRAF Mutant and BRAF Wild-Type Melanoma. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 278-288.	4.1	24
27	BRAF fusions identified in melanomas have variable treatment responses and phenotypes. <i>Oncogene</i> , 2019, 38, 1296-1308.	5.9	27
28	Biomarkers to predict immune-related adverse events with checkpoint inhibitors.. <i>Journal of Clinical Oncology</i> , 2019, 37, 131-131.	1.6	15
29	Adrenal metastases in malignant melanoma, is it a privileged site?. <i>Journal of Clinical Oncology</i> , 2019, 37, e21016-e21016.	1.6	2
30	Investigation of dielectric spectroscopy response in normal and cancerous biological tissues using S-parameter measurements. <i>Journal of Electromagnetic Waves and Applications</i> , 2018, 32, 956-971.	1.6	3
31	Successful treatment of disseminated Rosai-Dorfman disease with siltuximab. <i>Haematologica</i> , 2018, 103, e325-e328.	3.5	3
32	ALK Inhibitor Response in Melanomas Expressing <i>EML4-ALK</i> Fusions and Alternate <i>ALK</i> Isoforms. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 222-231.	4.1	38
33	Repigmentation of Human Vitiligo Skin by NB-UVB Is Controlled by Transcription of <i>GLI1</i> and Activation of the $\beta$ -Catenin Pathway in the Hair Follicle Bulge Stem Cells. <i>Journal of Investigative Dermatology</i> , 2018, 138, 657-668.	0.7	34
34	Authentication of M14 melanoma cell line proves misidentification of MDA-MB-435 breast cancer cell line. <i>International Journal of Cancer</i> , 2018, 142, 561-572.	5.1	37
35	CDK1 Interacts with Sox2 and Promotes Tumor Initiation in Human Melanoma. <i>Cancer Research</i> , 2018, 78, 6561-6574.	0.9	94
36	BH3 mimetics induce apoptosis independent of DRP-1 in melanoma. <i>Cell Death and Disease</i> , 2018, 9, 907.	6.3	24

#	ARTICLE	IF	CITATIONS
37	IMPACT web portal: oncology database integrating molecular profiles with actionable therapeutics. BMC Medical Genomics, 2018, 11, 26.	1.5	5
38	Targeting myeloid-derived suppressor cells using all-trans retinoic acid in melanoma patients treated with Ipilimumab. International Immunopharmacology, 2018, 63, 282-291.	3.8	145
39	APOBEC mutation drives early-onset squamous cell carcinomas in recessive dystrophic epidermolysis bullosa. Science Translational Medicine, 2018, 10, .	12.4	91
40	Comprehensive genomic profiling of acral and mucosal melanomas to support clinical decision making.. Journal of Clinical Oncology, 2018, 36, e21629-e21629.	1.6	0
41	Changes in allele frequencies of CSF3R and SETBP1 mutations and evidence of clonal evolution in a chronic neutrophilic leukemia patient treated with ruxolitinib. Haematologica, 2017, 102, e207-e209.	3.5	27
42	Whole-exome sequencing identifies recurrent SF3B1 R625 mutation and comutation of NF1 and KIT in mucosal melanoma. Melanoma Research, 2017, 27, 189-199.	1.2	121
43	Quality of Life and Performance Status From a Substudy Conducted Within a Prospective Phase 3 Randomized Trial of Concurrent Standard Radiation Versus Accelerated Radiation Plus Cisplatin for Locally Advanced Head and Neck Carcinoma: NRG Oncology RTOG 0129. International Journal of Radiation Oncology Biology Physics, 2017, 97, 667-677.	0.8	30
44	Fibroblast Subtypes Regulate Responsiveness of Luminal Breast Cancer to Estrogen. Clinical Cancer Research, 2017, 23, 1710-1721.	7.0	164
45	Kinase gene fusions in defined subsets of melanoma. Pigment Cell and Melanoma Research, 2017, 30, 53-62.	3.3	41
46	Use of a MCL-1 inhibitor alone to de-bulk melanoma and in combination to kill melanoma initiating cells. Oncotarget, 2017, 8, 46801-46817.	1.8	28
47	Acral Lentiginous Melanoma Harboring a <i>ROS1</i> Gene Fusion With Clinical Response to Entrectinib. JCO Precision Oncology, 2017, 1, 1-7.	3.0	309
48	Identification of somatic mutations and neoantigens to predict development of autoimmune adverse events to immune therapy in melanoma.. Journal of Clinical Oncology, 2017, 35, 19-19.	1.6	5
49	Genomic profiling of melanomas of unknown primary.. Journal of Clinical Oncology, 2017, 35, e21048-e21048.	1.6	0
50	A Survey of Computational Tools to Analyze and Interpret Whole Exome Sequencing Data. International Journal of Genomics, 2016, 2016, 1-16.	1.6	37
51	Isolating RNA from precursor and mature melanocytes from human vitiligo and normal skin using laser capture microdissection. Experimental Dermatology, 2016, 25, 805-811.	2.9	7
52	IMPACT: a whole-exome sequencing analysis pipeline for integrating molecular profiles with actionable therapeutics in clinical samples. Journal of the American Medical Informatics Association: JAMIA, 2016, 23, 721-730.	4.4	38
53	Association of sentinel lymph node diameter with melanoma metastasis. American Journal of Surgery, 2016, 212, 315-320.	1.8	5
54	Clonality of neutrophilia associated with plasma cell neoplasms: report of a SETBP1 mutation and analysis of a single institution series. Leukemia and Lymphoma, 2016, 57, 927-934.	1.3	12

#	ARTICLE	IF	CITATIONS
55	Identification of somatic mutations to predict development of autoimmune adverse events to immune therapy in melanoma.. Journal of Clinical Oncology, 2016, 34, 3041-3041.	1.6	4
56	Combining a GSI and BCL-2 inhibitor to overcome melanoma's resistance to current treatments. Oncotarget, 2016, 7, 84594-84607.	1.8	23
57	Disease diagnostics of biological tissues using free-space technique in terahertz frequency range. , 2015, , .		2
58	Combining a BCL2 Inhibitor with the Retinoid Derivative Fenretinide Targets Melanoma Cells Including Melanoma Initiating Cells. Journal of Investigative Dermatology, 2015, 135, 842-850.	0.7	30
59	Narrow Band Ultraviolet B Treatment for Human Vitiligo Is Associated with Proliferation, Migration, and Differentiation of Melanocyte Precursors. Journal of Investigative Dermatology, 2015, 135, 2068-2076.	0.7	86
60	SASH1 Is Involved in an Autosomal Dominant Lentiginous Phenotype. Journal of Investigative Dermatology, 2015, 135, 3192-3194.	0.7	23
61	Long Term Storage of Dry versus Frozen RNA for Next Generation Molecular Studies. PLoS ONE, 2014, 9, e111827.	2.5	38
62	Therapeutic monoclonal antibodies in human breast milk. Melanoma Research, 2014, 24, 177-180.	1.2	9
63	Somatic Mutations in MAP3K5 Attenuate Its Proapoptotic Function in Melanoma through Increased Binding to Thioredoxin. Journal of Investigative Dermatology, 2014, 134, 452-460.	0.7	20
64	Optical imaging of articular cartilage degeneration using near-infrared dipicolylamine probes. Biomaterials, 2014, 35, 7511-7521.	11.4	33
65	A highly recurrent RPS27 5'UTR mutation in melanoma. Oncotarget, 2014, 5, 2912-2917.	1.8	60
66	A comparison of cutaneous melanoma patients who recur following a negative sentinel lymph node biopsy to those with a positive sentinel lymph node biopsy.. Journal of Clinical Oncology, 2014, 32, 9065-9065.	1.6	0
67	Whole-genome sequencing identifies a recurrent functional synonymous mutation in melanoma. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 13481-13486.	7.1	147
68	A patient tumor transplant model of squamous cell cancer identifies PI3K inhibitors as candidate therapeutics in defined molecular bins. Molecular Oncology, 2013, 7, 776-790.	4.6	140
69	Management of external ear melanoma: the same or something different?. American Journal of Surgery, 2013, 206, 307-313.	1.8	22
70	Long-term Follow-up and Survival of Patients Following a Recurrence of Melanoma After a Negative Sentinel Lymph Node Biopsy Result. JAMA Surgery, 2013, 148, 456.	4.3	85
71	CtBP1 Is Expressed in Melanoma and Represses the Transcription of p16INK4a and Brca1. Journal of Investigative Dermatology, 2013, 133, 1294-1301.	0.7	27
72	Extracellular Vesicles Secreted from Cancer Cell Lines Stimulate Secretion of MMP-9, IL-6, TGF- $\beta$ 1 and EMMPRIN. PLoS ONE, 2013, 8, e71225.	2.5	40

#	ARTICLE	IF	CITATIONS
73	The RET G691S polymorphism is a germline variant in desmoplastic malignant melanoma. <i>Melanoma Research</i> , 2012, 22, 92-95.	1.2	11
74	A neoadjuvant biochemotherapy approach to stage III melanoma: analysis of surgical outcomes. <i>Immunotherapy</i> , 2012, 4, 679-686.	2.0	9
75	Desmoid Tumors in Pregnant and Postpartum Women. <i>Cancers</i> , 2012, 4, 184-192.	3.7	33
76	ALDH1A Isozymes are Markers of Human Melanoma Stem Cells and Potential Therapeutic Targets. <i>Stem Cells</i> , 2012, 30, 2100-2113.	3.2	241
77	Side Population Cells from Human Melanoma Tumors Reveal Diverse Mechanisms for Chemoresistance. <i>Journal of Investigative Dermatology</i> , 2012, 132, 2440-2450.	0.7	68
78	Sweat gland carcinoma versus metastatic breast carcinoma: A continued struggle among clinicians and dermatopathologists. <i>Journal of the American Academy of Dermatology</i> , 2012, 67, e156-e157.	1.2	2
79	Recovery of MicroRNA from Stored Human Peripheral Blood Samples. <i>Biopreservation and Biobanking</i> , 2011, 9, 29-33.	1.0	5
80	Transcriptome Profiling of Whole Blood Cells Identifies PLEK2 and C1QB in Human Melanoma. <i>PLoS ONE</i> , 2011, 6, e20971.	2.5	38
81	Exome sequencing identifies GRIN2A as frequently mutated in melanoma. <i>Nature Genetics</i> , 2011, 43, 442-446.	21.4	449
82	Stereotactic body radiation therapy for melanoma and renal cell carcinoma: impact of single fraction equivalent dose on local control. <i>Radiation Oncology</i> , 2011, 6, 34.	2.7	137
83	Unique Profile of Adenoid Cystic Carcinoma: A Triple Negative Breast Tumor With Paradoxical Features, a Case Report and Review of Literature. <i>Laboratory Medicine</i> , 2010, 41, 713-717.	1.2	2
84	p53 prevents progression of nevi to melanoma predominantly through cell cycle regulation. <i>Pigment Cell and Melanoma Research</i> , 2010, 23, 781-794.	3.3	59
85	Desmoid tumors of the right rectus abdominus muscle in postpartum women. <i>Archives of Gynecology and Obstetrics</i> , 2009, 279, 869-873.	1.7	10
86	Increased Survival From Stage IV Melanoma Associated With Fewer Regulatory T Cells. <i>Journal of Surgical Research</i> , 2009, 154, 13-20.	1.6	29
87	The anatomic distribution of melanoma and relationships with childhood nevus distribution in Colorado. <i>Melanoma Research</i> , 2009, 19, 252-259.	1.2	14
88	Presence of Dysregulated Immune Recovery (IMD) Following Autotransplant May Change the Type of Predominant Serum Light Chain and Elevate the Level in Patients with Multiple Myeloma (MM).. <i>Blood</i> , 2009, 114, 4870-4870.	1.4	0
89	An Outcome Study On Survival and Disease Control in Patients with High-Risk Multiple Myeloma (MM) for Relapse, Treated with High-Dose Melphalan Combined with Bortezomib for Autotransplant Followed by Post-Transplant Maintenance with Bortezomib and Lenalidomide.. <i>Blood</i> , 2009, 114, 3404-3404.	1.4	0
90	Unremitting Presence of Marrow Immunoglobulin Heavy Chain Gene Rearrangement (IGH-GR) 3 Months Following Autotransplant Is Associated with Poor Outcome in Disease Control in Patients with Multiple Myeloma (MM).. <i>Blood</i> , 2009, 114, 1807-1807.	1.4	0

#	ARTICLE	IF	CITATIONS
91	A phase II study of the heparanase inhibitor PI-88 in patients with advanced melanoma. <i>Investigational New Drugs</i> , 2008, 26, 89-94.	2.6	73
92	Immunomodulatory Therapy in Multiple Sclerosis and Breast Cancer Risk: A Case Report and Literature Review. <i>Clinical Breast Cancer</i> , 2008, 8, 449-452.	2.4	8
93	MicroRNA-137 Targets Microphthalmia-Associated Transcription Factor in Melanoma Cell Lines. <i>Cancer Research</i> , 2008, 68, 1362-1368.	0.9	257
94	Truncation in CCND1 mRNA alters miR-16-1 regulation in mantle cell lymphoma. <i>Blood</i> , 2008, 112, 822-829.	1.4	181
95	Gastrointestinal Melanoma or Clear Cell Sarcoma? Molecular Evaluation of 7 Cases Previously Diagnosed as Malignant Melanoma. <i>American Journal of Surgical Pathology</i> , 2008, 32, 858-866.	3.7	69
96	Recognition of double-stranded DNA by gold nanoprobe for malignant melanoma detection. , 2008, , .		0
97	EGFR-mutant lung adenocarcinoma in a patient with Li-Fraumeni syndrome. <i>Lancet Oncology</i> , The, 2007, 8, 559-560.	10.7	9
98	Genetic Mutations Involved in Melanoma: A Summary of Our Current Understanding. <i>Advances in Dermatology</i> , 2007, 23, 61-79.	2.0	29
99	Merkel cell carcinoma: evaluation of KIT (CD117) expression and failure to demonstrate activating mutations in the C-KIT proto-oncogene ? implications for treatment with imatinib mesylate. <i>Journal of Cutaneous Pathology</i> , 2007, 34, 324-329.	1.3	59
100	Platelet-derived growth factor receptor alpha mutational status and immunohistochemical expression in Merkel cell carcinoma: implications for treatment with imatinib mesylate. <i>Journal of Cutaneous Pathology</i> , 2007, 35, 070925001016012-???	1.3	26
101	Severe paraneoplastic hypoglycemia in a patient with a gastrointestinal stromal tumor with an exon 9 mutation: a case report. <i>BMC Cancer</i> , 2007, 7, 13.	2.6	32
102	Immunosuppressive Dendritic and Regulatory T Cells are Upregulated in Melanoma Patients. <i>Annals of Surgical Oncology</i> , 2007, 14, 2854-2860.	1.5	72
103	Treatment of Extranodal Marginal Zone Lymphoma and Primary Cutaneous B Cell Lymphoma with Rituximab: A Single Institution Experience.. <i>Blood</i> , 2007, 110, 4502-4502.	1.4	0
104	Size of sentinel node metastases predicts other nodal disease and survival in malignant melanoma. <i>American Journal of Surgery</i> , 2006, 192, 878-881.	1.8	56
105	A phase II open-label trial of apomine (SR-45023A) in patients with refractory melanoma. <i>Investigational New Drugs</i> , 2006, 24, 89-94.	2.6	8
106	Metastatic melanoma in the breast: A report of 27 cases. <i>Journal of Surgical Oncology</i> , 2006, 94, 101-104.	1.7	78
107	Microphthalmia transcription factor as a molecular marker for circulating tumor cell detection in blood of melanoma patients.. <i>Clinical Cancer Research</i> , 2006, 12, 1137-1143.	7.0	52
108	Phase II Multicenter Study of Neoadjuvant Biochemotherapy for Patients With Stage III Malignant Melanoma. <i>Journal of Clinical Oncology</i> , 2006, 24, 3157-3163.	1.6	54



#	ARTICLE	IF	CITATIONS
109	Serial Monitoring of Circulating Melanoma Cells During Neoadjuvant Biochemotherapy for Stage III Melanoma: Outcome Prediction in a Multicenter Trial. <i>Journal of Clinical Oncology</i> , 2005, 23, 8057-8064.	1.6	96
110	p16 expression in sentinel nodes with metastatic breast carcinoma: Evaluation of its role in developing triaging strategies for axillary node dissection and a marker of poor prognosis. <i>Human Pathology</i> , 2004, 35, 1524-1530.	2.0	12
111	The effect of flavopiridol on the growth of p16+ and p16~ melanoma cell lines. <i>Melanoma Research</i> , 2003, 13, 231-238.	1.2	10
112	The Genes and Genetics of Malignant Melanoma. <i>Journal of Cutaneous Medicine and Surgery</i> , 2002, 6, 229-235.	1.2	11
113	Management of primary cutaneous melanoma of the head and neck: The University of Colorado experience and a review of the literature. <i>Journal of Surgical Oncology</i> , 2001, 77, 179-185.	1.7	34
114	Pediatric Melanoma: Are Recent Advances in the Management of Adult Melanoma Relevant to the Pediatric Population. <i>The American Journal of Pediatric Hematology/Oncology</i> , 2000, 22, 428-432.	1.3	53
115	Positive tetracycline control of expression of p15INK4B from an Epstein-Barr autonomous plasmid in a human melanoma cell line. <i>Gene</i> , 2000, 242, 249-256.	2.2	2
116	Cardiac metastases from malignant melanoma. <i>Cancer</i> , 1999, 85, 78-84.	4.1	89
117	Surgical adjuvant active specific immunotherapy for patients with stage III melanoma: the final analysis of data from a phase III, randomized, double-blind, multicenter vaccinia melanoma oncolysate trial. <i>Journal of the American College of Surgeons</i> , 1998, 187, 69-79.	0.5	178
118	Increased Survival of Patients Treated With a Vaccinia Melanoma Oncolysate Vaccine. <i>Annals of Surgery</i> , 1997, 226, 198-206.	4.2	43
119	Deletion of the p53 Gene in a Patient with Aggressive Burn Scar Carcinoma. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1997, 17, 104-107.	2.4	36
120	Phase II Trial of Piritrexim and DTIC Using an Alternating Dose Schedule in Metastatic Melanoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1995, 18, 488-490.	1.3	8
121	A new myeloproliferative syndrome. <i>American Journal of Hematology</i> , 1995, 48, 186-191.	4.1	1
122	A phase III randomized, double-blind, multiinstitutional trial of vaccinia melanoma oncolysate-active specific immunotherapy for patients with stage II melanoma. <i>Cancer</i> , 1995, 75, 34-42.	4.1	116
123	The Treatment of Ovarian Cancer with a Gene Modified Cancer Vaccine: A Phase I Study. Tulane University, New Orleans, Louisiana. <i>Human Gene Therapy</i> , 1995, 6, 927-939.	2.7	47
124	Modified ilioinguinal node dissection for metastatic melanoma. <i>American Journal of Surgery</i> , 1995, 170, 647-650.	1.8	18
125	Treatment of Human Metastatic Malignant Melanoma with High Dose Oral Melatonin. , 1995, , 219-225.		5
126	Modification of the effect of tamoxifen, cisplatin, DTIC, and interferon-2b on human melanoma cells in culture by a mixture of vitamins. <i>Nutrition and Cancer</i> , 1994, 22, 233-245.	2.0	79



#	ARTICLE	IF	CITATIONS
127	Malignant melanoma: From subcutaneous nodule to brain metastasis. <i>Cancer Genetics and Cytogenetics</i> , 1994, 72, 16-23.	1.0	12
128	A phase II study of dacarbazine and cisplatin in combination with outpatient administered interleukin-2 in metastatic malignant melanoma. <i>Cancer</i> , 1993, 71, 3520-3525.	4.1	78
129	Malignant melanoma of the perineum. <i>Journal of Surgical Oncology</i> , 1993, 54, 185-189.	1.7	5
130	Cutaneous malignant melanoma. <i>Current Problems in Dermatology</i> , 1993, 5, 7-41.	0.0	5
131	Preferential chromosome 11q and/or 17q aberrations in short-term cultures of metastatic melanoma in resections from human brain. <i>Cancer Genetics and Cytogenetics</i> , 1992, 64, 118-126.	1.0	26
132	A case-control study of late recurrence of malignant melanoma. <i>American Journal of Surgery</i> , 1992, 164, 458-461.	1.8	23
133	Breast metastases from malignant melanoma. <i>Journal of Surgical Oncology</i> , 1992, 50, 27-29.	1.7	58
134	Low-dose $\alpha$ -interferon treatment of chronic myeloid leukemia. <i>American Journal of Hematology</i> , 1992, 39, 61-62.	4.1	5
135	Splenectomy vs. alpha interferon: A randomized study in patients with previously untreated hairy cell leukemia. <i>American Journal of Hematology</i> , 1992, 41, 13-18.	4.1	33
136	Role of Recombinant Alpha-Interferon in the Treatment of Advanced Cutaneous Malignant Melanoma. <i>Oncology</i> , 1991, 48, 365-368.	1.9	12
137	Malignant melanoma as a model for cancer education and prevention. <i>Journal of Cancer Education</i> , 1990, 5, 85-89.	1.3	6
138	Aggressive Non-Hodgkin's Lymphomas in AIDS: The University of Colorado Experience. <i>American Journal of the Medical Sciences</i> , 1990, 300, 345-349.	1.1	4
139	Cigarette smoking, blast crisis, and survival in chronic myeloid leukemia. <i>American Journal of Hematology</i> , 1990, 34, 1-4.	4.1	22
140	Surgical treatment of brain metastases in malignant melanoma. <i>Cancer</i> , 1990, 66, 2105-2110.	4.1	119
141	Intranasal administration of deferoxamine to iron overloaded patients. <i>American Journal of the Medical Sciences</i> , 1989, 297, 280-284.	1.1	4
142	Use of differentiation inducing agents in the myelodysplastic syndrome and acute non-lymphocytic leukemia. <i>American Journal of Hematology</i> , 1988, 28, 124-127.	4.1	40
143	Role of recombinant interferon alpha2 and cimetidine in patients with advanced malignant melanoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 1988, 114, 108-109.	2.5	14
144	Metastatic disease in patients with newly diagnosed malignant melanoma. <i>Journal of Surgical Oncology</i> , 1987, 35, 163-164.	1.7	39

#	ARTICLE	IF	CITATIONS
145	Isotretinoin Produces Significant Inhibition of Monocyte and Neutrophil Chemotaxis In Vivo in Patients With Cystic Acne. <i>Journal of Investigative Dermatology</i> , 1987, 89, 38-43.	0.7	56
146	Central nervous system metastases in malignant melanoma. <i>Cancer Treatment and Research</i> , 1987, , 155-163.	0.5	8
147	Diagnosis of Malignant Melanoma with Radiolabeled Monoclonal Antibodies: Current Status. <i>Drug Intelligence &amp; Clinical Pharmacy</i> , 1986, 20, 125-133.	0.4	2
148	Postburn serum inhibits in vitro production of colony-stimulating factor by mononuclear peripheral blood cells. <i>International Journal of Cell Cloning</i> , 1986, 4, 472-482.	1.6	0
149	Postburn serum inhibits in vitro production of colony-stimulating factor by mononuclear peripheral blood cells. <i>International Journal of Cell Cloning</i> , 1986, 4, 472-482.	1.6	6
150	Oncologic emergencies in primary care. <i>Postgraduate Medicine</i> , 1985, 78, 41-49.	2.0	1
151	Autografting for chronic myeloid leukemia in transformation. <i>American Journal of Hematology</i> , 1985, 18, 105-106.	4.1	4
152	Early vascular grafting to prevent upper extremity necrosis after electrical burns Commentary on indications for surgery. <i>Burns</i> , 1985, 11, 359-366.	1.9	12
153	Role of escharotomy and fasciotomy as a first aid measure in the early treatment of an electrically burned arm and wrist. <i>Burns</i> , 1985, 11, 419-422.	1.9	3
154	Thermal-crush injuries of the hands and forearms: an analysis of 60 cases. <i>Burns</i> , 1985, 11, 264-268.	1.9	6
155	Autologous marrow transplantation for patients with chronic myelogenous leukemia (CML) in blast crisis. <i>American Journal of Hematology</i> , 1984, 16, 105-112.	4.1	12
156	Vincristine, cisplatin, and bleomycin with surgery in the management of advanced metastatic nonseminomatous testis tumors. <i>Cancer</i> , 1984, 53, 203-209.	4.1	67
157	Vitamin E improves cell-mediated immunity in the burned mouse: A preliminary study. <i>Burns</i> , 1984, 11, 11-15.	1.9	9
158	Proliferating Cell Nuclear Antigen in Blast Crisis Cells of Patients With Chronic Myeloid Leukemia. <i>Journal of the National Cancer Institute</i> , 1984, , .	6.3	0
159	Schistosomal stimulation of eosinophil production by human bone marrow in vitro. <i>American Journal of Hematology</i> , 1983, 14, 207-213.	4.1	0
160	Detection of melanoma cells in bone marrow using monoclonal antibodies( a comparison of) <i>Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 147</i> 52, 949-953.	4.1	19
161	Familial leukemia and aplastic anemia associated with monosomy 7. <i>American Journal of Medicine</i> , 1983, 75, 756-762.	1.5	33
162	Regulation of Granulopoiesis following Severe Thermal Injury. <i>Journal of Trauma</i> , 1983, 23, 19-24.	2.3	56

#	ARTICLE	IF	CITATIONS
163	Treatment of advanced malignant melanoma with high-dose chemotherapy and autologous bone marrow transplantation Preliminary results—Phase I study. American Journal of Clinical Oncology: Cancer Clinical Trials, 1982, 5, 611-622.	1.3	24
164	The Anemia of Thermal Injury. Journal of Trauma, 1982, 22, 774-780.	2.3	16
165	Vitamin A levels in human bladder cancer. International Journal of Cancer, 1982, 30, 143-145.	5.1	22
166	Busulfan versus hydroxyurea in long-term therapy of chronic myelogenous leukemia. Cancer, 1982, 50, 1683-1686.	4.1	87
167	Urinary Granulocyte Colony-Stimulating Factor in Bilharziasis *. American Journal of Tropical Medicine and Hygiene, 1982, 31, 518-521.	1.4	6
168	Autologous Nonfrozen Bone Marrow Transplantation after Intensive Chemotherapy: A Pilot Study. Acta Haematologica, 1981, 66, 145-153.	1.4	20
169	Stem cell assays in the evaluation of myelotoxicity. Environmental Health Perspectives, 1981, 39, 51-58.	6.0	3
170	The Effect of Bacterial Infection on Granulopoiesis. Experimental Biology and Medicine, 1981, 167, 6-11.	2.4	7
171	Inappropriate Antidiuretic Hormone Secretion after High Dose Vinblastine. Journal of Urology, 1980, 123, 783-784.	0.4	23
172	Neutropenia in a patient with type IB glycogen storage disease: In vitro response to lithium chloride. Journal of Pediatrics, 1980, 97, 944-946.	1.8	31
173	In vivo and in vitro Effects of Lithium on Granulopoiesis in Human Neutropenic Disorders. Advances in Experimental Medicine and Biology, 1980, 127, 281-291.	1.6	9
174	Current Concepts of Abnormal Stem Cell Proliferation in Human Disease. Acta Haematologica, 1979, 62, 331-337.	1.4	3
175	Bacterial Stimulation of Serum Colony-Stimulating Activity and Neutrophil Production in Germ-Free Mice. Experimental Biology and Medicine, 1979, 162, 44-47.	2.4	14
176	Control factors of granulopoiesis in human serum. American Journal of Hematology, 1979, 6, 1-10.	4.1	12
177	Macrocytic anemia, thrombocytosis and nonlobulated megakaryocytes. American Journal of Medicine, 1979, 66, 946-950.	1.5	66
178	Mechanism of Poly I: Poly C Stimulation of Human Bone Marrow Colony Growth In Vitro. Experimental Biology and Medicine, 1978, 158, 151-155.	2.4	2
179	Effect of Levamisole on Human Granulopoiesis in Vitro. Experimental Biology and Medicine, 1977, 156, 359-364.	2.4	5
180	Bacterial Stimulation and Granulocyte Inhibition of Granulopoietic Factor Production. New England Journal of Medicine, 1977, 297, 1129-1134.	27.0	28

#	ARTICLE	IF	CITATIONS
181	Bacterial, serum and cellular modulation of granulopoietic activity. <i>Journal of Cellular Physiology</i> , 1977, 92, 145-153.	4.1	24
182	Granulopoietic studies in acute lymphocytic leukemia of children. <i>Blut</i> , 1977, 34, 77-88.	1.2	12
183	Felty's syndrome. <i>American Journal of Medicine</i> , 1976, 61, 29-32.	1.5	98
184	Clinical uses of semi-solid bone marrow cultures. <i>Blut</i> , 1976, 32, 1-12.	1.2	5
185	Efficacy of lithium in rheumatoid arthritis with granulocytopenia (felty's syndrome). <i>Arthritis and Rheumatism</i> , 1975, 18, 179-184.	6.7	64
186	Colony Stimulating Factor Levels in Human Serum and Urine Following Chemotherapy. <i>Experimental Biology and Medicine</i> , 1975, 148, 694-700.	2.4	6
187	Granulopoietic Activity of Urine and Cells from Patients with Chronic Granulocytic Leukemia. <i>Experimental Biology and Medicine</i> , 1974, 146, 499-503.	2.4	4
188	Granulocyte Colony Stimulating Activity and Vitamin B12 Binding Proteins in Human Urine. <i>British Journal of Haematology</i> , 1974, 28, 191-197.	2.5	7
189	GRANULOCYTOSIS IN NEOPLASIA. <i>Annals of the New York Academy of Sciences</i> , 1974, 230, 212-218.	3.8	161
190	Cyclic Leukocytosis in Chronic Myelogenous Leukemia: New Perspectives on Pathogenesis and Therapy. <i>Blood</i> , 1973, 41, 771-782.	1.4	89
191	The Effect of Concanavalin A on Bone Marrow Colony Formation in Vitro. <i>Experimental Biology and Medicine</i> , 1972, 140, 1441-1446.	2.4	8
192	The Effect of Serum from Patients with Acute Granulocytic Leukemia on Granulocyte Colony Formation in Vitro: A Search for Inhibitors. <i>Experimental Biology and Medicine</i> , 1972, 141, 515-518.	2.4	3
193	Colony Growth of Human Leukemic Peripheral Blood Cells In Vitro. <i>Blood</i> , 1971, 38, 500-508.	1.4	122
194	Colony Growth of Human Peripheral White Blood Cells In Vitro. <i>Blood</i> , 1971, 37, 136-141.	1.4	102
195	Leukopoietic Activity in Human Urine Following Operative Procedures. <i>Experimental Biology and Medicine</i> , 1971, 136, 29-33.	2.4	14
196	Human bone marrow colony growth in agar-gel. <i>Journal of Cellular Physiology</i> , 1970, 76, 77-84.	4.1	1,270
197	THE ENHANCING EFFECT OF BONE MARROW CELLS ON THE PRIMARY IMMUNE RESPONSE OF THE ISOLATED PERFUSED SPLEEN. <i>Journal of Experimental Medicine</i> , 1970, 131, 833-842.	8.5	11
198	Leukopoietic Activity in Human Urine. <i>New England Journal of Medicine</i> , 1970, 282, 1291-1297.	27.0	77

#	ARTICLE	IF	CITATIONS
199	Effect of Pilocarpine on Acid-Soluble Phosphate Compounds of Rat Following Hepatectomy.. Experimental Biology and Medicine, 1962, 111, 477-479.	2.4	2